In this issue:
When to avoid sentinel node biopsy
Palbociclib/fulvestrant improves OS in advanced disease
The current trastuzumab standard of 52 weeks appears optimal
Side effect profiles of ICIs in cancer
Risk of lung cancer with ACE inhibitors
Prescribing steroids at start of PD-(L)1 therapy
Nintedanib in refractory metastatic CRC
Treat left-sided colon and rectal tumours the same
Use fully-dosed adjuvant chemotherapy in obese colon cancer patients
FOLFOX-4 ± cetuximab in RAS wt metastatic CRC
Please login below to download this issue (PDF)